Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

John S. Millar,†,*† Katsunori Ikewaki,§ LeAnne T. Bloedon,*** Megan L. Wolfe,** Philippe O. Szapary,** and Daniel J. Rader†,*

Departments of Pharmacology* and Medicine,** Institute for Translational Research, and Therapeutics and Institute for Diabetes, Obesity, and Metabolism,† University of Pennsylvania, Philadelphia, PA 19104; and Division of Anti-Aging, Department of Internal Medicine,§ National Defense Medical College, Saitama 359-8513, Japan

Abstract Treatment with the peroxisome proliferator-activated receptor γ agonist rosiglitazone has been reported to increase HDL-cholesterol (HDL-C) levels, although the mechanism responsible for this is unknown. We sought to determine the effect of rosiglitazone on HDL apolipoprotein A-I (apoA-I) and apoA-II metabolism in subjects with metabolic syndrome and low HDL-C. Subjects were treated with placebo followed by rosiglitazone (8 mg) once daily. At the end of each 8 week treatment, subjects (n = 15) underwent a kinetic study to measure apoA-I and apoA-II production rate (PR) and fractional catabolic rate. Rosiglitazone significantly reduced fasting insulin and high-sensitivity C-reactive protein (hsCRP) and increased apoA-II levels. Mean apoA-I and HDL-C levels were unchanged following rosiglitazone treatment, although there was considerable individual variability in the HDL-C response. Rosiglitazone had no effect on apoA-I metabolism, whereas the apoA-II PR was increased by 23%. The change in HDL-C in response to rosiglitazone was significantly correlated with the change in apoA-II concentration but not to changes in apoA-I, measures of glucose homeostasis, or hsCRP. Treatment with rosiglitazone significantly increased apoA-II production in subjects with metabolic syndrome and low HDL-C but had no effect on apoA-I metabolism. The change in HDL-C in response to rosiglitazone treatment was unrelated to effects on apoA-I, instead being related to the change in the metabolism of apoA-II.—Millar, J. S., K. Ikewaki, L. T. Bloedon, M. L. Wolfe, P. O. Szapary, and D. J. Rader. Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL. J. Lipid Res. 2011. 52: 136–142.

Supplementary key words apolipoprotein A-I stable isotope thiazolidinedione lipoprotein kinetics high density lipoprotein

The metabolic syndrome consists of a cluster of abnormalities that include hypertension, abdominal obesity, impaired fasting glucose, elevated fasting triglyceride levels, and low HDL-cholesterol (HDL-C). Patients with metabolic syndrome are at increased risk of cardiovascular disease and, as a result, recommendations have been made to reduce the risk in these patients. These recommendations include therapeutic lifestyle changes and, if treatment goals are not met, pharmacological intervention (1).

Currently, few drugs are available that are suitable for treating patients with two components of the metabolic syndrome, insulin resistance and low HDL-C. Among treatments available for improving insulin resistance are the thiazolidinediones (TZDs) rosiglitazone and pioglitazone, which activate the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ). In addition to their insulin-sensitizing effects, TZDs have been shown to increase HDL-C levels in diabetic populations (2) by up to 14% for rosiglitazone and up to 19% for pioglitazone (3). These changes in HDL-C compare favorably to HDL-C changes achieved with other drugs currently approved to treat low HDL-C levels (4–7). Although rosiglitazone and pioglitazone both activate PPARγ, they each have a characteristic metabolic response in regard to plasma lipid levels, with rosiglitazone also increasing plasma triglyceride levels in the relatively short term, whereas pioglitazone does not (8).

The mechanisms responsible for the HDL-C-raising effects of TZDs are currently unknown. Studies that have measured apolipoprotein A-I (apoA-I) and apoA-II levels...
Consistent with these in vitro findings, Carreon-Torres et al. (18) recently reported that rosiglitazone increased apoA-I production in rabbits. In contrast, a study in patients with type 2 diabetes demonstrated that treatment with pioglitazone had no effect on apoA-I kinetics (19). To date, no studies have measured apoA-I kinetics in humans treated with rosiglitazone, and no study has examined the effect of TZDs on the kinetics of apoA-II in humans.

We conducted studies with rosiglitazone in subjects with metabolic syndrome and low HDL-C. These studies were conducted to test the hypothesis that rosiglitazone increases HDL-C by increasing apoA-I and apoA-II production in humans. Similar to what was reported for pioglitazone (19), the results show that the metabolism of apoA-I was unchanged in response to rosiglitazone treatment, whereas there was a significant increase in the PR of apoA-II. The greatest increase in HDL-C in response to rosiglitazone was associated with the change in apoA-II levels, with those subjects increasing the plasma concentration of apoA-II having the greatest increase in HDL-C in response to rosiglitazone.

MATERIALS AND METHODS

Subjects

Men and women between the ages of 18 and 75 years were recruited from the local area to participate in the study. All subjects had low HDL-C (<40 mg/dl for men, <50 mg/dl for women) and at least two additional risk factors for metabolic syndrome as defined by the Adult Treatment Panel III: abdominal obesity defined by increased waist circumference, hypertension or current treatment for hypertension, impaired fasting glucose without a diagnosis of diabetes, and fasting triglycerides >150 mg/dl and ≤800 mg/dl. Exclusion criteria included current treatment with statins or niacin; a history of cardiovascular disease including coronary artery disease or heart failure; a history of diabetes or recent treatment with diabetic medications; a history of renal disease or a serum creatinine level greater than 2.0 mg/dl; a history of testing HIV positive; being pregnant or lactating; a history of a serum creatinine level greater than 2.0 mg/dl; a history of testing HIV positive; being pregnant or lactating; a history of a serum creatinine level greater than 2.0 mg/dl; a history of testing HIV positive; being pregnant or lactating; a history of a serum creatinine level greater than 2.0 mg/dl; a history of testing HIV positive; being pregnant or lactating; a history of a serum creatinine level greater than 2.0 mg/dl; a history of testing HIV positive; being pregnant or lactating; a history of a serum creatinine level greater than 2.0 mg/dl; a history of testing HIV positive; being pregnant or lactating; and a serum creatinine level greater than 2.0 mg/dl. All subjects gave written, informed consent. All protocols and procedures were approved by the Human Investigational Review Board at the University of Pennsylvania.

Study design

This study was a single-site, single-blind, placebo-controlled, fixed-sequence study. A fixed-sequence design with placebo treatment followed by rosiglitazone treatment was selected to avoid potential carryover effects from rosiglitazone treatment. Eligible subjects visited the General Clinical Research Center (GCRC) at the University of Pennsylvania for baseline fasting blood collection. Prior to discharge, subjects were instructed to take placebo once daily for 8 weeks. At the end of the 8 week placebo treatment period, subjects were admitted to GCRC for an overnight kinetic study. Following the kinetic study, subjects were instructed to take rosiglitazone (8 mg) once daily for 8 weeks. At the end of the 8 week rosiglitazone treatment period, subjects returned to the GCRC for a second kinetic study. After this second kinetic study, the drug was discontinued and the subjects discharged.

Kinetic study

Apolipoprotein kinetics were measured as previously described (20). Briefly, subjects were fed a standardized meal representing 1/20th of their daily caloric intake hourly for 5 h. Participants were then given a bolus of [5,5,5-D₃]leucine (10 µmol/kg) immediately followed by a constant infusion of [5,5,5-D₃]leucine (10 µmol/kg/h). Hourly standardized meals were given throughout the kinetic study to maintain a constant rate of lipoprotein production. Blood samples were collected at various time points over a 15 h period, at which point the infusion was stopped. Lipoprotein fractions were isolated by sequential ultracentrifugation, and apolipoproteins were isolated by SDS-PAGE. Apolipoproteins were hydrolyzed, their amino acids derivatized, and their isolate enrichment analyzed by GC/MS. The fractional catabolic rates (FCRs) for HDL, apoA-I and apoA-II were determined using the WinSAAM modeling program by fitting a rising monoeponential curve that incorporated a secretory delay to the HDL apoA-I and apoA-II [5,5,5-D₃]leucine tracer data using a weighted least-squares approach (21). The apoA-I and apoA-II liver precursor pool enrichment was assumed to be equal to the maximal estimated VLDL apoB-100 enrichment (i.e., VLDL apoB-100 enrichment plateau). Pool sizes for apoA-I and apoA-II were calculated as plasma concentration (mg/dl) multiplied by the estimated plasma volume (0.45 dl/kg body weight). PRs were calculated by multiplying the FCR by the pool size using the formula PR (mg/kg/day) = FCR (pool/s/day) • pool size (mg/kg body weight/pool).

Biochemical measurements

Plasma lipids were measured from EDTA plasma collected after a 12 h fast in a Centers for Disease Control and Prevention-standardized laboratory. Plasma total cholesterol (TC), VLDL-C (d < 1.006 g/ml fraction), HDL-C, and triglycerides were measured enzymatically on a Cobas Fara II autoanalyzer (Roche Diagnostic Systems, Inc.; Basel, Switzerland) using Sigma reagents (Sigma Chemical Co.; St. Louis, MO). LDL-C levels were determined by subtracting VLDL-C and HDL-C from the TC measurement. ApoA-I, apoB, apoC-II, apoC-III, apoE, and lipoprotein[a] (Lp[a]) were measured with immunoturbidimetric assays using Wako reagents (Wako Chemicals USA, Inc.; Richmond, VA). HDL particle sizes were measured using MD-Science (LipoScience; Raleigh, NC). High-sensitivity C-reactive protein (hsCRP) was measured with an ultra high-sensitivity latex turbidimetric immunoassay. High-sensitivity C-reactive protein (hsCRP) was measured with an ultra high-sensitivity latex turbidimetric immunoassay (Wako Chemicals USA, Inc.). Insulin levels were measured by radioimmunoassay (Linco Research, Inc.). Insulin resistance was estimated with the homeostasis model assessment of insulin resistance (HOMA-IR) calculated as [plasma insulin (µIU/ml) × plasma glucose (mmol/l)]/22.5.

Cellular cholesterol efflux studies

Cholesterol efflux from Fu5AH rat hepatoma cells to patient HDL was obtained following precipitation of apoB-containing lipoproteins with polyethylene glycol, as previously described (22). Fu5AH cells efflux cholesterol primarily via the scavenger receptor...
tor class B type I (SR-BI) and aqueous diffusion pathways (23). Efflux was measured over a 4 h period on samples collected at the end of the placebo and rosiglitazone treatment periods.

Statistical analysis
Diff erences between treatment groups were determined using a paired t test. Diff erences for nonnormally-distributed data were determined using the Wilcoxon sign rank test. Analyses were performed using GraphPad Prism, Version 3.02 (GraphPad Software, Inc.). Stepwise multiple regression was conducted using Intercooled Stata, Version 9. A two-tailed P value of less than 0.05 was considered statistically signif i cant.

RESULTS

Subjects
Seventeen subjects (nine male, eight female) enrolled in the study. The mean age of the subjects was 50.6 ± 10.5 years, with nine Caucasian and eight African-American subjects. Two subjects voluntarily withdrew from the study prior to initiating rosiglitazone treatment, and fifteen subjects completed all study-related visits. Baseline subject characteristics are shown in Table 1. Body mass index (BMI) ranged from 25.8 to 42.6 kg/m², with the mean falling within the obesity range (>30.0 kg/m²). Five of the enrolled subjects were smokers.

Treatment with rosiglitazone (8 mg once daily) was well-tolerated and there were no serious adverse events reported. One subject was found to have trace edema in lower extremities after 8 weeks on rosiglitazone, which resolved within 2 weeks of drug discontinuation and was judged as possibly related to treatment. A second subject gained an unexplained 5.8 kg between baseline and 8 weeks on placebo and another 2.1 kg after being on rosiglitazone for 8 weeks that was judged as possibly related to treatment. Neither subject had symptoms of congestive heart failure or ischemic cardiovascular events. Because the second subject with unexplained weight gain was not in a steady state during the study period, the results for this subject were excluded from all analyses.

Effects on plasma lipoproteins
The plasma lipid levels at the end of the placebo and rosiglitazone phases are shown in Table 2. There was an 11% increase in plasma TC in response to rosiglitazone that was due to a significant increase in the VLDL cholesterol level. There were no signifcant changes in triglyceride, LDL-C, or HDL-C levels following rosiglitazone treatment. Plasma nonesterifed FA levels were signifcantly decreased (~36%) following rosiglitazone treatment. ApoA-I and apoB levels in plasma were unchanged following rosiglitazone treatment, whereas apoA-II, apoE, apoC-III, and Lp(a) levels in plasma were all signifcantly increased.

Effect on fasting glucose, insulin, and hsCRP
Fasting glucose, insulin, and hsCRP levels at the end of the placebo and rosiglitazone phases are shown in Table 2. There was no change in fasting plasma glucose, whereas there were signifcant reductions in fasting insulin (~22%) and the HOMA-IR in response to rosiglitazone treatment. Plasma levels of hsCRP were signifcantly reduced following rosiglitazone treatment.

Effects on HDL particle concentration, size, and composition
We assessed HDL particle concentrations and particle size by NMR (Table 3). Consistent with the lack of change in the HDL-C concentration, there was no change in HDL particle concentra tion. There was, however, a change in the HDL size distribution, with an increase in medium-sized HDL and a decrease in small HDL.

The lipid composition and apolipoprotein content of HDL isolated by ultracentrifugation was determined at the end of the placebo and rosiglitazone treatment periods (Table 3). Treatment with rosiglitazone signifcantly increased the percent phospholipid content and content of apoE in the HDL fraction. There was a trend toward the percent triglyceride content in HDL with rosiglitazone treatment being reduced.

Effects on serum cholesterol efflux capacity
Treatment with rosiglitazone significantly increased the ability of HDL to promote cholesterol efflux from Fu5AH cells in vitro studies. After 8 weeks of treatment with rosiglitazone, there was a 30% increase in the ability of HDL to promote cholesterol efflux (1.17 ± 0.41% efflux/4 h vs. 1.45 ± 0.44% efflux/4 h, placebo vs. rosiglitazone; P = 0.03). The percent change in HDL levels in response to rosiglitazone treatment was signifcantly correlated with the percent change in cholesterol efflux (r = 0.79; P = 0.0008).

Effects on apoA-I and A-II metabolism
The results for changes in apoA-I and apoA-II metabolism in response to rosiglitazone are summarized in Table 4. There was no signifcant change in the apoA-I pool size following rosiglitazone treatment, as compared with placebo treatment, although there was a trend toward a lower pool size (~7%). There was also no signifcant change in the apoA-I PR or FCR in response to rosiglitazone treatment.

In contrast, the apoA-II pool size was signifcantly increased in subjects treated with rosiglitazone. There was a signifcant increase in the apoA-II PR (23%) following rosiglitazone treatment, whereas the apoA-II FCR showed no signifcant change, although the individual changes in

| TABLE 1. Baseline characteristics of the subjects enrolled in the study |
|---------------------------------------------------------------|
| Subject characteristics (n = 17)                              |
| Age (years), mean ± SD                                       | 50.6 ± 10.5 |
| Male sex, n (%)                                              | 9 (53)      |
| Race                                                         |
| White, n (%)                                                 | 9 (53)      |
| African-American, n (%)                                      | 8 (47)      |
| BMI (kg/m²), mean ± SD                                       | 31.5 ± 4.0  |
| Current smoker, n (%)                                        | 5 (29)      |

BMI, body mass index.
this variable ranged from $-24\%$ to $32\%$. Interestingly, the correlation between the percent change in the apoA-II PR and the percent change in the apoA-II pool size in response to rosiglitazone was not statistically significant ($r = -0.17; P = 0.55$) due to a concomitant increase in the apoA-II FCR in many subjects. Instead, there was a significant inverse correlation between the percent change in the apoA-II concentration and the percent change in the apoA-II pool size ($r = -0.72; P = 0.004$), indicating that the subjects with reduced or unchanged apoA-II FCR had the greatest change in apoA-II pool size.

### Determinants of the change in HDL-C levels

The HDL-C response to rosiglitazone treatment was heterogeneous, ranging from $-20\%$ to $35\%$. To attempt to identify the factors that determine the HDL-C response to rosiglitazone, correlations were conducted between the percent change in HDL-C and the percent change in the following variables: plasma apoA-I and apoA-II concentrations, apoA-I and apoA-II FCR and PR, triglyceride, apoC-III, nonesterified FAs, fasting insulin, fasting glucose, HOMA, and hsCRP (Table 5). Of these, the percent changes in the apoA-II concentration, the apoA-II FCR, the apoC-III concentration, and the nonesterified FA concentration were significant correlates. When adjusting for BMI and smoking, only the percent changes in the apoA-II concentration and the nonesterified FA concentration remained significant correlates with the change in HDL-C.

To determine whether the variables identified as significant correlates were independent predictors of the percent change in HDL-C levels, these variables were included in a stepwise regression model. When this was done, the percent change in the plasma apoA-II and apoC-III concentrations remained significant ($P = 0.0001$) and accounted for 75% of the change in the HDL-C concentration. When controlling for both BMI and smoking in the model, only the percent change in the plasma apoA-II remained a significant predictor of the percent change in HDL-C in response to rosiglitazone, accounting for 70% of the change, whereas apoC-III was of marginal significance in the model ($P = 0.07$). The relationship between the percent change in apoA-II concentration and the percent change in HDL-C is shown in Fig. 1.

### DISCUSSION

Activation of the nuclear receptor PPARγ with rosiglitazone improves insulin sensitivity in patients with insulin resistance and type 2 diabetes. The mechanism by which this occurs is not completely understood but may involve reduction of hepatic glucose production and enhanced glucose uptake into adipose tissue following upregulation of the glucose transporter GLUT4 (24, 25). In addition to improving insulin sensitivity, rosiglitazone also reduces plasma nonesterified FAs and inflammatory cytokines and increases adiponectin, all of which are thought to contribute to improved insulin sensitivity (9).
ApoA-II FCR

JOURNAL OF LIPID RESEARCH

ApoA-II concentration 0.80

ApoA-I PR 0.00 0.18

ApoA-I concentration 0.35 0.44

ApoC-III

Triglyceride

HsCRP

HOMA 0.08 0.27

Fasting insulin 0.21 0.42

Nonesterified FAs

tered by rosiglitazone, including (27). A number of genes encoding proteins that are al-

clear receptor hepatic nuclear factor (HNF)-4

Rosiglitazone has been shown to increase levels of the nu-
derue to improvement in insulin sensitivity (not shown).

evidence to suggest that the increase in the apoA-II PR was

be due to transactivation of PPAR

II following rosiglitazone treatment. Although this could

or FCR, we found a significant increase in the PR of apoA-

tion of PPAR

in liver (26). However, subsequent reports

have indicated that rosiglitazone increases apoA-I production

rabbits (18) and the human hepatoma cell line, HepG2 (16), via partial activation of PPARs. We found

that there was no change in the PR of the PPARs target

apoA-I following rosiglitazone treatment. Our results sug-

gest that if there is activation of PPARs by rosiglitazone, it

is relatively weak and insufficient to activate APOA1 tran-

scription at doses given in humans, similar to what was re-

ported in humans treated with pioglitazone (19).

In contrast to the lack of change in apoA-I production

or FCR, we found a significant increase in the PR of apoA-

II following rosiglitazone treatment. Although this could be
due to transactivation of PPARs, it is also possible that

there are direct or indirect effects of PPARγ activation that

lead to increased transcription of APOA2. There was no
evidence to suggest that the increase in the apoA-II PR was
due to improvement in insulin sensitivity (not shown). Rosiglitazone has been shown to increase levels of the nu-
clear receptor hepatic nuclear factor (HNF)-4α in rat liver

(27). A number of genes encoding proteins that are al-
tered by rosiglitazone, including APOA2, APOC3, and LPA,
have HNF-4α binding sequences in their promoter regions,
suggesting that HNF-4α activation may have con-
tributed to the increase in apoA-II production (28). Another possible mechanism by which rosiglitazone could
increase the apoA-II PR is through reduction in circulating
levels of inflammatory cytokines (9). ApoA-II mRNA
levels and transcription (29) are decreased in rodents in
response to acute inflammation (30), owing to both direct
effects of cytokines on APOA2 gene expression (31) and
indirect effects of NF-κB interfering with HNF4 activation
of gene expression (32).

In general, treatment with rosiglitazone results in an
increase in HDL-C (33). However, some studies have re-
ported that HDL-C levels were unchanged or decreased
following rosiglitazone treatment despite improvement
in glucose homeostasis (13, 14). In the current study in-
volving subjects with metabolic syndrome, there was no
change in the mean HDL-C level in response to rosiglita-
zone. However, the response among individual subjects
was variable, with some subjects increasing HDL-C levels,
wheras others showed a decrease. A previous report sug-
gests that the HDL-C response to PPARγ agonists is re-
lated to improvement in insulin sensitivity (34). However,
we found that there was no significant correlation be-
tween changes in measures of glucose homeostasis and
changes in HDL-C. Instead, the change in HDL-C was
positively correlated with the change in apoA-II concentra-
tion in plasma. ApoA-II is known to influence HDL
remodeling by cholesteryl ester transfer protein (CETP)
and may inhibit cholesterol transfer between HDL and
other lipoproteins, leading to an increase in HDL size
and composition (35). Interestingly, we found that the
change in apoA-II concentration significantly correlated
with the change in the apoA-II FCR. Ng and coworkers
(36) recently reported that the apoA-II FCR was influ-
enced by changes in adiposity following weight loss. Be-
cause rosiglitazone promotes changes in adiposity, it is
possible that it influences apoA-II metabolism, with ef-
ficts on liver, to increase apoA-II production, and effects
on adipose tissue that could influence the apoA-II FCR.
Although speculative, effects on both apoA-II production
and catabolism could contribute to the reported variabil-
ity in the HDL response to rosiglitazone.

In addition to increasing HDL size, we also found that
rosiglitazone altered the composition and apolipoprotein
content of HDL. The change in HDL lipid composition
may be related to effects on the CETP-mediated exchange
of triglyceride between VLDL and HDL. There may also be

TABLE 4. ApoA-I and apoA-II kinetic parameters measured at the end of the placebo and rosiglitazone treatment periods (n = 14)

| Parameter                  | Placebo          | Rosiglitazone     | % Change | P     |
|----------------------------|------------------|-------------------|----------|-------|
| ApoA-I pool size           | 3.715 ± 817      | 3.426 ± 808       | −7%      | 0.14  |
| ApoA-I PR                  | 9.81 ± 2.47      | 9.47 ± 4.04       | −3%      | 0.69  |
| ApoA-I FCR                 | 0.238 ± 0.084    | 0.244 ± 0.095     | 4%       | 0.70  |
| ApoA-II pool size          | 1.105 ± 282      | 1.315 ± 350       | 19%      | <0.0001 |
| ApoA-II PR                 | 2.33 ± 0.67      | 2.97 ± 0.94       | 23%      | <0.0001 |
| ApoA-II FCR                | 0.190 ± 0.060    | 0.197 ± 0.067     | 4%       | 0.37  |

Data are expressed as mean ± SD. FCR, fractional catabolic rate; PR, production rate.

In addition to improving insulin sensitivity, rosiglitazone may have beneficial effects on lipoprotein metab-
olism, possibly mediated through transactivation of PPARα in liver. Initial studies with rosiglitazone in rats examined the
mechanisms responsible for its lipid-altering effects and concluded that there was no significant transactivation
of PPARα in liver (26). However, subsequent reports have indicated that rosiglitazone increases apoA-I production
in rabbits (18) and the human hepatoma cell line, HepG2 (16), via partial activation of PPARs. We found
that there was no change in the PR of the PPARα target
apoA-I following rosiglitazone treatment. Our results sug-

TABLE 5. Correlations between the percent change in HDL-C and the percent changes in candidate HDL-C determinants in response to rosiglitazone treatment (n = 14)

| Parameter                  | Correlation Coefficient, Unadjusted | Correlation Coefficient, Adjusted for BMI and Smoking |
|----------------------------|------------------------------------|-----------------------------------------------|
| ApoA-I concentration       | 0.35                               | 0.44                                          |
| ApoA-I FCR                 | −0.26                              | −0.14                                         |
| ApoA-I PR                  | 0.00                               | 0.18                                          |
| ApoA-II concentration      | 0.80                               | 0.83                                          |
| ApoA-II FCR                | −0.53*                             | −0.51                                         |
| ApoA-II PR                 | −0.07                              | −0.05                                         |
| Fasting insulin            | 0.21                               | 0.42                                          |
| Fasting glucose            | −0.25                              | −0.26                                         |
| HOMA                       | 0.08                               | 0.27                                          |
| HsCRP                      | −0.11                              | −0.14                                         |
| Triglyceride               | −0.45                              | −0.50                                         |
| ApoC-III                   | −0.60*                             | −0.50                                         |
| Nonesterified FAs          | −0.66*                             | −0.68*                                        |

* P ≤ 0.05.

* P = 0.001.
changes in phospholipid transfer protein, whose expression increases in response to acute inflammatory stimulation and may be expected to decrease following rosiglitazone treatment (37). We also observed an increase in the apoE content of HDL during rosiglitazone treatment, an effect that should be interpreted with caution because there are significant losses of apoE from HDL during isolation by ultracentrifugation. These changes in lipid and apolipoprotein content were associated with a significant increase in the efflux of cholesterol from the hepatic cell line Fu5AH to HDL during the rosiglitazone treatment period, as compared with placebo, indicating a change in the functionality of HDL. Fu5AH cells efflux cholesterol primarily through SR-BI and aqueous diffusion (23). Increases in both the apoE content and percent phospholipid content of HDL have previously been shown to enhance the ability of HDL to accept cholesterol from cells via SR-BI (38–40). These changes in HDL composition and functionality would be expected to be antiatherogenic because they would be expected to promote reverse cholesterol transport. However, a recent report indicated that rosiglitazone has no effect on the progression of atherosclerosis, compared with placebo (41), similar to the results of the RECORD trial that showed no effect of rosiglitazone on cardiovascular risk (42). Thus, other metabolic effects of rosiglitazone may neutralize any beneficial effects of the drug on HDL levels and functionality. It is also possible that raising HDL enriched with apoA-II adversely influences HDL function and is of no cardiovascular benefit. The role of apoA-II in reducing cardiovascular risk is currently controversial and its benefits have yet to be established (43, 44).

There are a number of limitations to this study. These include the relatively small sample size, which was powered to detect a 10% change in the apoA-I and apoA-II-associated metabolic parameters. The study is also of relatively short duration. It is possible that some metabolic effects of rosiglitazone treatment only become apparent with longer term treatment. Another limitation is the fixed-sequence design of the study. This design was selected to avoid residual drug effects that may have lingered beyond a washout period. This design does not control for temporal changes in lipoprotein metabolism that are unrelated to the study drug.

In conclusion, treatment of subjects with metabolic syndrome with rosiglitazone (8 mg) had no effect on apoA-I metabolism, whereas apoA-II production was significantly increased. Subjects in which apoA-II levels increased had the greatest rise in HDL, which was associated with significant stimulation of cholesterol efflux from cells in vitro. The results indicate that the change in HDL-C in response to rosiglitazone treatment is unrelated to changes in apoA-I metabolism, and instead is related primarily to changes in apoA-II levels.

The authors wish to acknowledge the technical expertise of Jennifer Dykhouse, Phyllis May, Anna DiFlorio, and Linda Morrell and the nursing staff and Investigational Drug Service at the GCRC at the University of Pennsylvania. The authors would also like to thank the study subjects for their participation.

REFERENCES

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285:2486–2497.
2. Chiquette, E., G. Ramirez, and R. Defronzo. 2004. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch. Intern. Med. 164:2097–2104.
3. Goldberg, R. B., D. M. Kreisberg, M. A. Deeg, J. B. Buse, A. J. Zagar, J. A. Pinaire, M. H. Tan, M. A. Khan, A. T. Perez, and S. J. Jacober. 2005. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547–1554.
4. Capuzzi, D. M., J. R. Guyton, J. M. Morgan, A. C. Goldberg, R. A. Kreisberg, O. A. Brusco, and J. Brody. 1998. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol. 82:74U–81U.
5. Schafer, E. J., and B. F. Asztalos. 2006. The effects of statins on high-density lipoproteins. Curr. Atheroscler. Rep. 8:41–49.
6. Barter, P. J., and K. A. Rye. 2008. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol. 28:39–46.
7. Hartweg, J., A. J. Farmer, R. Perera, R. R. Holman, and H. A. Neil. 2007. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia. 50:1593–1602.
8. Goldberg, R. B. 2006. Impact of thiazolidinediones on serum lipoprotein levels. Curr. Atheroscler. Rep. 8:397–404.
9. Samaha, F. F., P. O. Szapary, N. Iqbal, M. M. Williams, L. T. Bledoen, A. Kochar, M. L. Wolfe, and D. J. Rader. 2006. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26:624–630.
10. Freed, M. I., R. Ratner, S. M. Marcovina, M. M. Kreider, N. Biswas, B. R. Cohen, and J. D. Brunzell. 2002. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol. 90:947–952.
11. Wagner, J. A., P. J. Larson, S. Weiss, J. L. Miller, T. W. Doebber, M. S. Wu, D. E. Moller, and K. M. Gottsdiner. 2005. Individual and combined effects of peroxisome proliferator-activated receptor [gamma] agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J. Clin. Pharmacol. 45:504–513.
12. Sarafidis, P. A., A. N. Lasaridis, P. M. Nilsson, T. F. Mouslech, A. D. Higdon-Makekou, P. C. Stafylas, K. A. Kazakos, J. G. Yovos, and A. A. Tourkantonis. 2005. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism. 54:1236–1242.
13. Derosa, G., A. F. Cicero, A. Gaddi, P. D. Ragonesi, E. Fogari, G. Bertone, L. Ciccarelli, and M. N. Piccinni. 2004. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin. Ther. 26:744–754.
14. Derosa, G., A. V. Gaddi, M. N. Piccinni, S. Salvadoro, L. Ciccarelli, E. Fogari, M. Ghelfi, I. Ferrari, and A. F. Cicero. 2006. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. *Diabetes Obes. Metab.* 9: 197–205.

15. Furch, T., D. Junquero, A. Delmon, and J. Pauwels. 2002. Pharmacological analysis of wild-type alpha, gamma, and delta subtypes of human peroxisome proliferator-activated receptor. *Naunyn Schmiedebergs Arch. Pharmacol.* 365: 133–140.

16. Sakamoto, J., H. Kimura, S. Moriyama, H. Odaka, Y. Momose, Y. Sugiyama, and H. Sawada. 2000. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. *Biochem. Biophys. Res. Commun.* 278: 704–711.

17. Qin, S., T. Liu, V. S. Kamanna, and M. R. Briggs. 2009. Rosiglitazone modifies HDL structure and increases HDL-apoA1 synthesis and catabolic rates. *Clin. Chim. Acta.* 401: 37–41.

18. Millar, J. S., M. E. Brousseau, M. R. Diffenderfer, P. H. Barrett, F. K. Welty, A. Faraqi, M. L. Wolfe, C. Nartupha, A. G. Digenio, J. P. Mancuso, et al. 2006. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. *Arterioscler. Thromb. Vasc. Biol.* 26: 1350–1356.

19. Ikewaki, K., D. J. Rader, J. R. Schafer, T. Fairwell, L. A. Zech, and H. B. Brewer, Jr. 1993. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. *J. Lipid Res.* 34: 2207–2215.

20. Zimetti, F., G. K. Weibel, M. Duong, and G. H. Rothblat. 2006. Measurement of cholesterol bidirectional flux between cells and lipoproteins. *J. Lipid Res.* 47: 605–613.

21. Rothblat, G. H., M. de la Llera-Moya, V. Atger, G. Kellner-Weibel, D. L. Williams, and M. C. Phillips. 1999. Cell cholesterol efflux: integration of old and new observations provides new insights. *J. Lipid Res.* 40: 781–796.

22. Hofmann, C., K. Lorenz, and J. R. Colca. 1991. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. *Endocrinology.* 129: 1915–1925.

23. Armoni, M., N. Kritz, C. Harel, F. Bar-Youseph, H. Chen, M. J. Quon, and E. Karmieli. 2005. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. *J. Biol. Chem.* 280: 30614–30623.

24. Lefebvre, A. M., J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J. C. Fruchart, C. Fievet, J. Auwerx, and B. Staels. 2005. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. *J. Clin. Invest.* 115: 1323–1332.

25. Quon, J. L., J. Paul, V. Atger, A. Cogny, T. Soni, M. de la Llera-Moya, G. Rothblat, and N. Moatti. 1997. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from rat liver to human serum. *Arterioscler. Thromb. Vasc. Biol.* 17: 2685–2691.

26. Chroni, A., T. J. Nieland, K. E. Kypros, M. Krieger, and V. I. Zannis. 2006. SR-BI mediates cholesterol efflux via its interaction with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. *Biochemistry.* 45: 13132–13143.

27. Varghese, A. M., S. Yee, F. C. Chan, L. A. Crowe, N. G. Keenan, D. G. Johnston, and D. J. Pensel. 2009. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. *J. Cardiovasc. Magn. Reson.* 11: 24.

28. Home, P. D., S. J. Pocock, H. Beck-Nielsen, P. S. Curtis, R. Gomis, M. Hanefeld, N. P. Jones, M. Komajda, and J. J. McMurray. 2009. Rosiglitazone evaluated for cardiovascular outcomes in oral anti-diabetic therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet.* 373: 2125–2135.

29. Birjumohan, R. S., G. M. Dallinga-Thie, J. A. Kuivenhoven, E. T. Stroes, J. D. Otvis, N. J. Wareham, R. Luben, J. J. Kastelein, E. T. Khaw, and S. M. Boekholdt. 2007. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. *Circulation.* 116: 2029–2035.

30. Blanco-Vaca, F., J. C. Escola-Gil, J. M. Martin-Campos, and J. Julve. 2001. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. *J. Lipid Res.* 42: 1727–1739.